BIIB

Dollar change -0.14
Percentage change -0.09	%

Peers: VRTX GILD REGN AMGN MRK PFE BMY LLY JNJ NBIX

| Held by: VTI VOO VO QQQ SPY IVV VTV VOE XLV IBB

Index	NDX, S&P 500	P/E	14.12	EPS (ttm)	11.07	Insider Own	0.71%	Shs Outstand	145.70M	Perf Week	-2.82%
Market Cap	22.78B	Forward P/E	9.33	EPS next Y	16.75	Insider Trans	-0.05%	Shs Float	144.68M	Perf Month	-9.66%
Income	1.62B	PEG	3.19	EPS next Q	3.41	Inst Own	89.29%	Short Float	1.86%	Perf Quarter	-21.48%
Sales	9.23B	P/S	2.47	EPS this Y	11.57%	Inst Trans	0.03%	Short Ratio	1.91	Perf Half Y	-30.75%
Book/sh	112.28	P/B	1.39	EPS next Y	1.99%	ROA	5.72%	Short Interest	2.70M	Perf Year	-34.67%
Cash/sh	11.66	P/C	13.41	EPS next 5Y	4.43%	ROE	10.47%	52W Range	153.62 - 268.30	Perf YTD	-39.59%
Dividend Est.	-	P/FCF	11.70	EPS past 5Y	-18.05%	ROI	7.60%	52W High	-41.74%	Beta	-0.08
Dividend TTM	-	Quick Ratio	0.80	Sales past 5Y	-4.53%	Gross Margin	67.77%	52W Low	1.76%	ATR (14)	3.98
Dividend Ex-Date	-	Current Ratio	1.26	EPS Y/Y TTM	9.71%	Oper. Margin	22.96%	RSI (14)	31.49	Volatility	2.31% 2.45%
Employees	7570	Debt/Eq	0.41	Sales Y/Y TTM	-3.98%	Profit Margin	17.50%	Recom	1.86	Target Price	246.96
Option/Short	Yes / Yes	LT Debt/Eq	0.30	EPS Q/Q	665.41%	Payout	0.00%	Rel Volume	1.31	Prev Close	156.46
Sales Surprise	1.29%	EPS Surprise	8.15%	Sales Q/Q	-2.44%	Earnings	Oct 30 BMO	Avg Volume	1.41M	Price	156.32
SMA20	-2.21%	SMA50	-10.03%	SMA200	-23.43%	Trades		Volume	1,846,942	Change	-0.09%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-10-24	Resumed	BofA Securities	Neutral	$178
Dec-09-24	Downgrade	Jefferies	Buy → Hold	$250 → $180
Nov-18-24	Downgrade	Needham	Buy → Hold
Nov-15-24	Initiated	Wolfe Research	Peer Perform
Nov-14-24	Initiated	Citigroup	Neutral	$190
Oct-31-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$285 → $204
Oct-10-24	Resumed	Raymond James	Mkt Perform
Feb-14-24	Reiterated	Needham	Buy	$305 → $300
Feb-14-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$315 → $240
Jan-24-24	Downgrade	UBS	Buy → Neutral	$311 → $276
Dec-20-23	Resumed	Cantor Fitzgerald	Overweight	$311
Dec-07-23	Upgrade	Raymond James	Mkt Perform → Outperform	$283
Sep-06-23	Initiated	HSBC Securities	Buy	$360
Jul-27-23	Initiated	Scotiabank	Sector Outperform	$327
Jul-24-23	Reiterated	UBS	Buy	$346 → $335
May-01-23	Upgrade	Guggenheim	Neutral → Buy	$270 → $350
Apr-17-23	Upgrade	Piper Sandler	Neutral → Overweight	$280 → $346
Oct-26-22	Upgrade	Goldman	Neutral → Buy	$220 → $370
Oct-13-22	Upgrade	Stifel	Hold → Buy	$223 → $299
Oct-07-22	Upgrade	Argus	Hold → Buy	$300

Show Previous Ratings

Dec-09-24 01:44PM	Biogen Downgraded On Pipeline Setbacks And Leqembi Sales Slowdown (Benzinga)
12:27PM	Biogen cut at Jefferies as '2025 has a tough setup' (Investing.com)
Dec-05-24 08:30AM	Is Eli Lilly Stock A Buy After Zepbound Bests Wegovy In A Head-To-Head Study? (Investor's Business Daily)
08:30AM	GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners (Business Wire)
Dec-04-24 06:31PM	'LEQEMBI' (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico (PR Newswire)
07:44AM	Loading…
Dec-02-24 07:44AM	Analyst Report: Biogen Inc. (Morningstar Research)
Nov-28-24 06:08AM	Why Biogen Inc. (BIIB) is One of the Cheapest Stocks to Buy on Robinhood? (Insider Monkey)
Nov-27-24 07:31PM	'LEQEMBI' (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea (PR Newswire)
09:15AM	Why Is Biogen Inc. (BIIB) Among the Worst Performing Healthcare Stocks in 2024? (Insider Monkey)
Nov-26-24 02:23PM	Eli Lilly Pops After Biden Proposes Medicare Cover Obesity Drugs. Is Lilly Stock A Buy? (Investor's Business Daily)
Nov-22-24 11:00AM	Is Eli Lilly Stock A Sell After Kennedy-Tied Woes Rankled Shares? (Investor's Business Daily)
07:45AM	Goldman Sachs: Biogen Inc. (BIIB) Is A Top Growth Investor Stock (Insider Monkey)
06:45AM	Biogen price target lowered to $207 from $251 at Mizuho (TipRanks)
Nov-20-24 01:32PM	Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside (Benzinga)
Nov-19-24 07:06PM	Biogen Inc. (BIIB): Among the Best Genomics Stocks to Buy Right Now (Insider Monkey)
01:00AM	Loading…
01:00AM	Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity (GlobeNewswire)
Nov-18-24 01:18PM	Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026 (Benzinga)
11:30AM	Needham downgrades Biogen on slow growth of Alzheimer's drug (Investing.com)
07:00AM	Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ (GlobeNewswire)
04:25AM	Is Biogen Inc. (BIIB) A Cheap NASDAQ Stock To Invest In Now? (Insider Monkey)
12:40AM	Analyst Report: Biogen Inc. (Morningstar Research)
Nov-14-24 02:20PM	European committee takes a second look at Alzheimer's drug and now says it should be approved (Associated Press Finance)
01:53PM	5 Healthcare Stocks to Buy in a Beaten-Up Sector (Barrons.com)
01:29PM	Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease (PR Newswire)
09:54AM	Citi initiates coverage on 5 new biotech stocks (Investing.com)
Nov-12-24 09:40AM	Here's Why Biogen Inc. (BIIB) is a Strong Value Stock (Zacks)
Nov-11-24 06:51PM	Analyst Report: Biogen Inc. (Morningstar Research)
Nov-08-24 09:33AM	Analyst Report: Biogen Inc. (Morningstar Research)
Nov-05-24 09:40AM	Are Investors Undervaluing Biogen (BIIB) Right Now? (Zacks)
Nov-04-24 09:35AM	Biogen (BIIB) Loses -6.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
08:03PM	Loading…
Oct-31-24 08:03PM	Eisai Completes Rolling Submission to US FDA for LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status (PR Newswire)
10:51AM	Biogen down as Morgan Stanley cuts rating on sluggish Alzheimers drug launch (Investing.com)
03:07AM	Biogen Inc (BIIB) Q3 2024 Earnings Call Highlights: Navigating Revenue Declines and Strategic ... (GuruFocus.com)
Oct-30-24 07:30PM	Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference (GlobeNewswire)
04:27PM	Biogen Sinks. Why A Surprise Boost From Its Alzheimer's Drug Wasn't Enough. (Investor's Business Daily)
02:01PM	Analyst Report: Biogen Inc. (Morningstar Research)
01:46PM	Biogen and Neomorph enter molecular glue degrader deal (Pharmaceutical Technology)
01:45PM	Biogen (BIIB) Q3 2024 Earnings Call Transcript (Motley Fool)
09:30AM	Biogen (BIIB) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
08:05AM	Biogen Inc. (BIIB) Q3 Earnings and Revenues Surpass Estimates (Zacks)
07:38AM	Biogen, Sage admit a defeat in major depression (BioPharma Dive)
07:28AM	Biogen Earnings Top Views; Alzheimer's Drug Leqembi Gaining Momentum (Investor's Business Daily)
07:18AM	Eli Lilly stock sinks after Q3 earnings miss Wall Street expectations (Yahoo Finance)
07:07AM	Biogen raises annual earnings guidance, tops Q3 estimates; shares up (Investing.com)
07:02AM	Biogen Raises Forecast as Alzheimers Drug Leqembi Shows Signs of Growth (Bloomberg)
06:54AM	Biogen raises annual profit forecast as new treatments boost earnings (Reuters)
06:15AM	Biogen optimistic as new products gain traction (BioPharma Dive)
Oct-29-24 06:00PM	Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer's, Rare, and Immunological Diseases (GlobeNewswire)
05:03PM	Eli Lilly Q3 earnings misses Wall Street expectations, stock slips 10% in pre-market (Yahoo Finance)
05:03PM	Eli Lilly Q3 earnings expected to beat Wall Street expectations (Yahoo Finance)
08:00AM	Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer (GlobeNewswire)
05:54AM	Biogen refreshes its C-suite; Novartis writes down MorphoSys assets (BioPharma Dive)
Oct-28-24 09:16AM	Seeking Clues to Biogen (BIIB) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics (Zacks)
08:30AM	Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025 (GlobeNewswire)
Oct-26-24 08:15PM	Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024 (GlobeNewswire)
Oct-24-24 07:30AM	Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference (GlobeNewswire)
Oct-23-24 10:01AM	Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
09:40AM	Here's Why Biogen Inc. (BIIB) is a Strong Value Stock (Zacks)
03:19AM	Analyst Report: Biogen Inc. (Morningstar Research)
Oct-22-24 07:30AM	Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024 (GlobeNewswire)
Oct-20-24 04:28PM	Biogen Inc. (BIIB): An Oversold Large Cap Stock To Buy Now (Insider Monkey)
02:20PM	Is Biogen Inc. (BIIB) the Best QQQ Stock to Buy According to Analysts? (Insider Monkey)
Oct-19-24 11:19AM	Biogen Inc. (BIIB): Worst Performing NASDAQ Stock in 2024 (Insider Monkey)
Oct-17-24 10:11AM	After Series Of Trial Setbacks, Sage Therapeutics To Lay Off One-Third Workforce (Benzinga)
Oct-16-24 03:02PM	State Street Corp's Strategic Acquisition of Biogen Inc Shares (GuruFocus.com)
08:45AM	Biogen (BIIB): Pioneering CNS Treatments and Future Growth Prospects (Insider Monkey)
Oct-10-24 12:10PM	Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report? (Zacks)
12:01PM	Biogen scores breakthrough status for anti-rejection transplant medication (Pharmaceutical Technology)
Oct-09-24 07:30AM	Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients (GlobeNewswire)
Oct-08-24 08:52AM	Talkiatry Expands Postpartum Depression Care Services to Close Gaps in Maternal Mental Healthcare (PR Newswire)
07:30AM	New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA (GlobeNewswire)
Oct-07-24 09:40AM	Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term (Zacks)
Oct-03-24 09:25AM	UBS sees more downside and than upside in Biogen stock (Investing.com)
Oct-02-24 06:52AM	Biogen scrapped stroke drug helps patients walk independently in Phase III trial (Clinical Trials Arena)
Oct-01-24 08:46PM	Biogen Inc. (BIIB): Among the Best Bargain Stocks to Buy In October (Insider Monkey)
Sep-26-24 10:37AM	Biogen Terminates Collaboration With Sage Therapeutics For Neurological Disorder Candidate (Benzinga)
Sep-24-24 11:05AM	Biogen stock opened higher on positive lupus readout (Investing.com)
08:19AM	Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial (Benzinga)
06:33AM	UCB and Biogen lupus drug succeeds in Phase III, but data yet to be released (Clinical Trials Arena)
01:00AM	UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024 (GlobeNewswire)
Sep-23-24 09:00PM	Biogen, UCB get the lupus data theyve waited two decades for (BioPharma Dive)
Sep-20-24 08:00AM	Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Aflibercept Biosimilar, OPUVIZ (GlobeNewswire)
Sep-16-24 09:40AM	Here's Why Biogen Inc. (BIIB) is a Strong Value Stock (Zacks)
01:52AM	Hope remains that Roches prasinezumab can overcome recent string of failures in Parkinsons disease (Clinical Trials Arena)
Sep-13-24 06:55AM	Subcutaneous Tecentriq gets FDA OK; Gilead shot succeeds in second HIV trial (BioPharma Dive)
Sep-12-24 03:32PM	Healthcare Stocks Have Popped. Consider These 2 That Havent. (Barrons.com)
07:30AM	Biogen Board Appoints Two New Independent Directors (GlobeNewswire)
Sep-06-24 12:53PM	Biogens higher Spinraza dose shows better efficacy in Phase II/III trial (Pharmaceutical Technology)
07:00AM	Pandemic Darling Moderna Needs a Reality Check (The Wall Street Journal)
Sep-05-24 12:00PM	Long-Term Investor News: Biogen, Seritage Growth, Arbor Realty, and Five Below Investors are Encouraged to Contact Johnson Fistel, LLP for Their Options (GlobeNewswire)
Sep-04-24 10:43AM	Biogen's Higher Dose Spinraza Shows To Slow Neurodegeneration Faster In Infants With Rare Neuromuscular Disorder (Benzinga)
08:15AM	High-dose Spinraza meets study goal; Top Dyne executives exit (BioPharma Dive)
07:30AM	Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA (GlobeNewswire)
Aug-26-24 10:15AM	Long Term Investor News: Biogen, Seritage Growth, Arbor Realty, and Five Below Investors are Encouraged to Contact Johnson Fistel, LLP for Their Options (GlobeNewswire)
Aug-22-24 01:45PM	Biogen's Alzheimer's Drug Secures UK Approval, But An Independent Agency Does Not Recommend Reimbursement (Benzinga)
12:33PM	Eisais Leqembi deemed too costly for NHS (Pharmaceutical Technology)
09:40AM	Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term (Zacks)
07:38AM	UK approves Leqembi, but reimbursement may not follow (BioPharma Dive)
05:10AM	Leqembi (lecanemab) Authorized for Early Alzheimer's Disease in Great Britain (PR Newswire)
Aug-20-24 09:00AM	Do Options Traders Know Something About Biogen (BIIB) Stock We Don't? (Zacks)

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Singhal Priya	Head of Development	Dec 06 '24	Option Exercise	0.00	426	0	5,742	Dec 09 04:57 PM
Singhal Priya	Head of Development	Dec 09 '24	Sale	157.21	110	17,293	5,426	Dec 09 04:57 PM
Kramer Robin	Chief Accounting Officer	Dec 06 '24	Option Exercise	0.00	351	0	6,578	Dec 09 04:56 PM
Singhal Priya	Officer	Dec 09 '24	Proposed Sale	157.21	110	17,293		Dec 09 10:33 AM
Grogan Jane	Head of Research	Nov 01 '24	Option Exercise	0.00	695	0	695	Nov 04 04:39 PM
Singhal Priya	Head of Development	Aug 30 '24	Option Exercise	0.00	1,668	0	6,554	Sep 05 06:00 AM
Singhal Priya	Head of Development	Sep 03 '24	Sale	204.22	431	88,019	5,316	Sep 05 06:00 AM
Singhal Priya	Officer	Sep 03 '24	Proposed Sale	204.22	431	88,019		Sep 03 01:00 PM
Keeney Adam	Head of Corporate Development	May 01 '24	Option Exercise	0.00	938	0	938	May 03 08:00 PM
Singhal Priya	Head of Development	Apr 02 '24	Sale	213.09	93	19,817	4,886	Apr 03 08:24 PM
Murphy Nicole	Head of Pharm Ops and Tech	Apr 01 '24	Option Exercise	0.00	240	0	9,751	Apr 03 08:11 PM
Singhal Priya	Head of Development	Feb 22 '24	Sale	221.23	262	57,962	4,886	Feb 26 07:54 PM
ALEXANDER SUSAN H	EVP Chief Legal Officer	Feb 16 '24	Option Exercise	0.00	5,037	0	52,506	Feb 21 09:39 PM
Gregory Ginger	EVP, Human Resources	Feb 16 '24	Option Exercise	0.00	4,704	0	14,341	Feb 21 09:36 PM
Izzar Rachid	Head of Global Product Strat.	Feb 16 '24	Option Exercise	0.00	2,017	0	10,014	Feb 21 09:33 PM
Kramer Robin	Chief Accounting Officer	Feb 16 '24	Option Exercise	0.00	1,345	0	6,354	Feb 21 09:31 PM
MCDONNELL MICHAEL R	EVP, Chief Financial Officer	Feb 16 '24	Option Exercise	0.00	6,720	0	20,692	Feb 21 09:29 PM
Murphy Nicole	Head of Pharm Ops and Tech	Feb 16 '24	Option Exercise	0.00	1,260	0	9,624	Feb 21 09:28 PM
Singhal Priya	Head of Development	Feb 16 '24	Option Exercise	0.00	1,208	0	5,429	Feb 21 09:27 PM
Singhal Priya	Head of Development	Feb 16 '24	Sale	221.49	108	23,921	5,148	Feb 21 09:27 PM
Rowinsky Eric K	Director	Feb 15 '24	Buy	222.54	455	101,256	20,629	Feb 20 09:13 PM
Gregory Ginger	EVP, Human Resources	Feb 09 '24	Option Exercise	0.00	2,158	0	11,778	Feb 13 06:14 PM
Singhal Priya	Head of Development	Feb 09 '24	Option Exercise	0.00	1,212	0	5,309	Feb 13 06:06 PM
Singhal Priya	Head of Development	Feb 12 '24	Sale	239.45	419	100,330	4,516	Feb 13 06:06 PM
Murphy Nicole	Head of Pharm Ops and Tech	Feb 09 '24	Option Exercise	0.00	2,272	0	9,529	Feb 13 06:04 PM
MCDONNELL MICHAEL R	EVP, Chief Financial Officer	Feb 09 '24	Option Exercise	0.00	3,257	0	17,555	Feb 13 06:03 PM
Kramer Robin	Chief Accounting Officer	Feb 09 '24	Option Exercise	0.00	833	0	5,523	Feb 13 06:01 PM
Izzar Rachid	Head of Global Product Strat.	Feb 09 '24	Option Exercise	0.00	1,515	0	9,081	Feb 13 06:00 PM
ALEXANDER SUSAN H	EVP Chief Legal Officer	Feb 09 '24	Option Exercise	0.00	2,575	0	50,021	Feb 13 05:56 PM
ALEXANDER SUSAN H	EVP Chief Legal Officer	Feb 08 '24	Option Exercise	0.00	2,190	0	48,101	Feb 09 08:16 PM
Gregory Ginger	EVP, Human Resources	Feb 08 '24	Option Exercise	0.00	1,635	0	10,118	Feb 09 08:14 PM
Izzar Rachid	Head of Global Product Strat.	Feb 08 '24	Option Exercise	0.00	2,043	0	8,187	Feb 09 08:11 PM
Kramer Robin	Chief Accounting Officer	Feb 08 '24	Option Exercise	0.00	788	0	4,943	Feb 09 08:06 PM
MCDONNELL MICHAEL R	EVP, Chief Financial Officer	Feb 08 '24	Option Exercise	0.00	2,335	0	15,063	Feb 09 08:03 PM
Murphy Nicole	Head of Pharm Ops and Tech	Feb 08 '24	Option Exercise	0.00	2,101	0	7,895	Feb 09 08:01 PM
Singhal Priya	Head of Development	Feb 01 '24	Option Exercise	0.00	1,828	0	5,292	Feb 05 06:38 PM
Singhal Priya	Head of Development	Feb 02 '24	Sale	245.93	634	155,920	4,097	Feb 05 06:38 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Biogen Inc

Upgrade your FINVIZ experience